(Reuters) - Pfizer Inc will pay $55 million plus interest to settle charges that Wyeth promoted its acid reflux drug Protonix for unapproved uses and made unproven claims about the medicine, the U.S.

(Reuters) – Pfizer Inc will pay $55 million plus interest to settle charges that Wyeth promoted its acid reflux drug Protonix for unapproved uses and made unproven claims about the medicine, the U.S.

Teva had launched its generic version of Protonix in Dec 2007, well ahead of the patent expiry date of Jan 2011. Teva’s sales of generic Protonix prior to Jan 2011 were about $1.1 billion. While Teva ...

Pantoprazole is a generic delayed-release oral tablet prescribed for certain conditions affecting the gastrointestinal system. It’s available as the brand-name drug Protonix. The cost of pantoprazole ...

Pfizer is going after Teva for lost profits and damages. --Courtesy of Pfizer Turns out, Teva Pharmaceutical Industries' ($TEVA) at-risk launch of copycat Protonix ...

Teva Pharmaceutical Industries ($TEVA) knew it was taking a gamble in 2007 when it launched a generic version of Protonix before its patent expiration--just not a $2 ...

Pantoprazole (as sodium) 40mg; per vial; pwd for IV infusion after reconstitution and dilution; contains edetate disodium. Supplied in a single-dose vial as a white to off-white freeze-dried powder ...

NEW YORK Wyeth on Tuesday announced the U.S. launch of its own generic version of Protonix (pantoprazole) in response to December’s at-risk launch of a generic version by Teva Pharmaceuticals.

NEW YORK, April 23 (Reuters) - A New Jersey jury handed a victory to Pfizer Inc on Friday, ruling that the patent on its Protonix acid reflux drug is valid and infringed by Teva Pharmaceutical ...

Wyeth said late yesterday that it's introducing its own generic of heartburn blockbuster Protonix, the WSJ reports. That means the company was unable to come to a settlement with Teva over the generic ...